糖尿病削弱原发性膜性肾病对抗CD20治疗的应答
本回顾性队列研究经倾向评分匹配纳入207例接受抗CD20治疗的成人原发性膜性肾病患者,比较合并糖尿病(72例)与不合并糖尿病(135例)者的疗效。结果显示两组B细胞清除和免疫学缓解无显著差异,但糖尿病患者9个月和12个月蛋白尿缓解率显著更低,安全性相似。
要点
- 合并糖尿病的膜性肾病患者抗CD20治疗后蛋白尿缓解率显著低于无糖尿病患者。
- 两组B细胞清除率和免疫学缓解率无显著差异。
- 糖尿病患者的治疗应答较差,需关注血糖控制及补充抗CD20剂量。
核心结论
- 尽管B细胞清除等效,合并糖尿病的原发性膜性肾病患者对抗CD20治疗的应答低于无糖尿病患者。
- 建议对合并糖尿病的膜性肾病患者加强血糖控制、对应答不佳者早期补充抗CD20剂量并考虑联合免疫抑制方案。
研究设计与样本
- 回顾性队列研究,纳入接受至少一个完整疗程抗CD20抗体治疗的成人原发性膜性肾病患者。
- 采用倾向评分匹配(1:2),匹配因素为年龄、性别、基线估算肾小球滤过率、尿蛋白和PLA2R抗体状态。
- 匹配后共纳入207例患者,其中合并糖尿病组72例,无糖尿病组135例。
主要发现
- 12个月随访期间,两组B细胞清除率和免疫学缓解率无统计学显著差异。
- 无糖尿病组9个月总体缓解率显著高于糖尿病组(94% vs. 77%;OR=4.55,95%CI=1.52-12.50,P<0.01)。
- 无糖尿病组12个月总体缓解率显著高于糖尿病组(97% vs. 86%;OR=5.26,95%CI=1.25-20.00,P<0.05)。
- 亚组分析显示糖尿病患者在多个分层中应答一致较差。
- 两组安全性特征相似。
关键数值与推荐
- 主要结局为3、6、9、12个月蛋白尿缓解(完全或部分)。
- 次要结局包括免疫学缓解、B细胞清除和肾脏参数变化。
临床怎么用
- 对合并糖尿病的原发性膜性肾病患者,抗CD20治疗后应更密切监测蛋白尿应答。
- 血糖控制可能影响治疗应答,需优化糖尿病管理。
- 对糖尿病患者的应答不佳可考虑早期补充抗CD20剂量或联合免疫抑制治疗。
局限性
- 回顾性研究设计可能引入选择偏倚和残留混杂。
- 样本量有限,亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Primary membranous nephropathy (MN) and diabetes mellitus (DM) are common comorbidities, yet the impact of DM on the response to anti-CD20 monoclonal antibody therapy in MN remains unclear. We hypothesized that despite comparable B-cell depletion, MN patients with comorbid DM would exhibit a reduced treatment response compared to nondiabetic MN patients. METHODS: In this retrospective cohort study, we included adults with primary MN who received at least one complete course of anti-CD20 antibody therapy. Propensity score matching (1:2) was applied based on age, sex, baseline estimated glomerular filtration rate, urinary protein, and PLA2R antibody status. The primary outcome was remission (complete or partial) of proteinuria at 3, 6, 9, and 12 months. Secondary outcomes included immunological remission, B-cell depletion, and changes in renal parameters. Multivariable logistic regression, Kaplan-Meier analysis, and subgroup analyses were used to compare outcomes between MN patients with (MN + DM) and without diabetes (MN). RESULTS: After matching, 207 patients were included (72 MN + DM, 135 MN). B-cell depletion and immunological remission rates showed no statistically significant differences between groups over the 12-month follow-up period. However, MN patients had significantly higher overall remission rates at 9 months [94% vs. 77%; odds ratio (OR) = 4.55, 95% confidence interval (CI) = 1.52-12.50, P < 0.01] and at 12 months (97% vs. 86%; OR: 5.26, 95% CI: 1.25-20.00, P < 0.05). Subgroup analyses confirmed consistently poorer responses in diabetic patients across multiple strata. Safety profiles were similar between groups. CONCLUSION: Despite equivalent B-cell depletion, MN with DM patients show a reduced response to anti-CD20 antibody therapy relative to nondiabetic patients, underscoring that tight glycemic control, early supplementary anti-CD20 dosing for poor response, and combined immunosuppressive regimens may enhance their clinical outcomes.
引用
- Xu X, Wu M, Zhao F, et al. Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion. Nephrol Dial Transplant. 2026. PMID: 41860432. doi:10.1093/ndt/gfag065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。